ONCY

NASD Oncolytics Biotech Inc.
Nov 19, 2026 · 4:03 PM ET LAST TRADE Market Closed

$0.3990 ↓ -0.0413 (-9.38%) Trading Down from the previous close of $0.4403, $0.0610 below the day’s high of $0.4600

YTD change
-54.35%
vs 20-day SMA
-5.47%
vs 200-day SMA
-51.34%

Price ranges

Previous day
$0.3765 $0.4454
open $0.3899 close $0.4403
+$0.0504 (+12.93%)
Today
$0.3902 $0.4600
open $0.4434 now $0.3990
-$0.0444 (-10.01%)
Past week
$0.3334 $0.4454
from $0.4116 now $0.3990
-$0.0126 (-3.06%)
Past month
$0.3334 $0.5200
from $0.5114 now $0.3990
-$0.1124 (-21.98%)
This year
$0.3334 $1.3000
from $0.8740 now $0.3990
-$0.4750 (-54.35%)

Price & Performance

-0.33 (-43.19%) / 6M

$0.2823$0.5607$0.8392$1.12May 19Aug 19Nov 18

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Not So Good
  • The stock is 94.6% away from all-time highs of $7.4000
  • ONCY is down 54% since the beginning of the year
  • ONCY is down 62% over the past 12 months
  • ONCY is down 22% over the past 1 month
  • 7% of all ONCY investors are betting against ONCY

ONCY reads not so good: price sits below both the 20- and 200-day averages, the 12-month move is -57.7%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable No
EPS $-0.08
Earnings momentum -32.4% Quarterly EPS growth
Quarterly change -32.4%

Valuation

P/E ratio N/A
Enterprise value $54.3M
Beta 1.27

Balance sheet & scale

IncomeN/A
RevenueN/A
Cash$2.4M
Debt$410.0
Income / Debt N/A

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeNASD
Sector Professional, Scientific, and Technical Services
Industry Group Scientific Research and Development Services
Market cap $54.3M

Oncolytics Biotech, Inc. engages in the provision of development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolation of the reovirus that induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses. The company was founded by Matthew C. Coffey and Bradley George Thompson on April 2, 1998 and is headquartered in Calgary, Canada.

Competitor comparison

TickerCompany PriceChange
REGN Regeneron Pharmaceuticals, Inc. $945.53 -1.28%
IQV IQVIA Holdings Inc $257.84 +0.09%
CRL Charles River Laboratories International, Inc. $333.25 +0.33%
ICLR ICON Plc $195.16 +0.07%
IT Gartner, Inc. $178.84 -2.52%

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.